Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Zhi-Xin Xu
First-In-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-In-Class Dual MEK/RAF Inhibitor in Patients With Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
Related publications
First-In-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients With Advanced Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
A Phase I Dose‐Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination With Erlotinib in Patients With Advanced Solid Tumors
Oncologist
Cancer Research
Medicine
Oncology
A First-In-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients With Advanced Solid Malignancies
Clinical Cancer Research
Cancer Research
Oncology
First‐in‐human Phase I Study of E7090, a Novel Selective FGFR Inhibitor, in Patients With Advanced Solid Tumors
Cancer Science
Cancer Research
Medicine
Oncology
A Phase I Dose-Escalation Study of Intravenous Panobinostat in Patients With Lymphoma and Solid Tumors
Investigational New Drugs
Oncology
Pharmacology
First-In-Human Phase I Study of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
First-In-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients With Advanced Solid Tumors
Molecular Cancer Therapeutics
Cancer Research
Oncology
Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients With Advanced Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
Erratum To: First-In-Human Phase I Study of SOR-C13, a TRPV6 Calcium Channel Inhibitor, in Patients With Advanced Solid Tumors
Investigational New Drugs
Oncology
Pharmacology
